Calliditas and STADA partner to commercialize IgA Nephropathy in Europe
BAD VILBEL, GERMANY: Calliditas Therapeutics AB and STADA Arzneimittel AG announced today that they have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A…